A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects
Latest Information Update: 07 Dec 2021
At a glance
- Drugs CJ 40010 (Primary)
- Indications Coxsackievirus infections; Enterovirus A infections
- Focus Adverse reactions
- Sponsors HK inno.N
Most Recent Events
- 09 Dec 2019 New trial record
- 01 Dec 2019 Status changed from not yet recruiting to recruiting.